fMRI Data from Clinical Trial Demonstrate a Proposed Mechanism of Action for the Efficacy of Vayarin® Plus in Adults with ADHD
22. Januar 2019 08:20 ET
|
VAYA Pharma Inc.
Study Abstract Presented at the 2019 APSARD Annual Meeting in Washington, DC COLUMBIA, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc, and...
New Clinical Trial Demonstrates Efficacy and Safety of Vayarin® Plus for Adults with ADHD
26. Oktober 2018 10:14 ET
|
VAYA Pharma Inc.
COLUMBIA, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc, and leader in developing specialty nutrition and medical food products, announced today that...
New Data from Adult ADHD Clinical Trial to be Presented at the 65th Annual AACAP Meeting
09. Oktober 2018 08:30 ET
|
VAYA Pharma Inc.
COLUMBIA, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc., and leader in developing specialty nutrition and medical food products, announced today the...
VAYA™ Pharma Launches Vayarin® Plus Medical Food for the Management of ADHD in Adults and Adolescents
04. Juni 2018 09:23 ET
|
VAYA Pharma Inc.
COLUMBIA, MD., June 04, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Industries Ltd. (LSE:FRUT) (TASE:FRUT) and a leader in specialty nutrition and medical food...
VAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods
02. Mai 2017 08:30 ET
|
VAYA Pharma Inc.
BALTIMORE, May 02, 2017 (GLOBE NEWSWIRE) -- VAYA Pharma, a division of Enzymotec Ltd (NASDAQ:ENZY) and innovator of lipid-based medical foods, today announced the availability of new three-month...
CORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study
24. Januar 2017 13:03 ET
|
VAYA Pharma Inc.
BALTIMORE, Jan. 24, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline January 10, 2017 by VAYA Pharma, please note that in the first paragraph under Results at a Glance, "38...
Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study
10. Januar 2017 11:33 ET
|
VAYA Pharma Inc.
BALTIMORE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Up to 75 percent of individuals with Attention Deficit Hyperactivity Disorder (ADHD) experience emotional dysregulation, according to Research in...
New Survey Shows Nearly 3 Out of 4 Children Treated for ADHD Have Taken a “Drug Holiday”
04. Mai 2016 09:00 ET
|
VAYA Pharma Inc.
National VAYA™ Pharma Survey Reveals Drug Holidays are Mostly Prompted by Physicians and the Desire to Reduce Medication Side Effects BALTIMORE, May 04, 2016 (GLOBE NEWSWIRE) -- Approximately...
New Retrospective Study Shows PS-Omega-3 Medical Food Effective in Managing ADHD
26. April 2016 11:07 ET
|
VAYA Pharma Inc.
Nearly a Third of Children Who Experienced a Benefit While Taking PS-Omega-3 Were Also Able to Reduce Their ADHD Medication Dose BALTIMORE, April 26, 2016 (GLOBE NEWSWIRE) -- According to a new...